Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.
The conversation discusses hair loss, scalp buildup, and treatments like Nizoral shampoo, Minoxidil, and dietary changes to address seborrheic dermatitis and iron deficiency. The user plans to improve their hair condition with a good routine, Nizoral, and diet adjustments.
Vitamin E and K deficiencies due to exocrine pancreatic insufficiency may affect hair growth. A scalp biopsy is recommended to check for autoimmune-related hair loss.
Creatine does not cause or worsen hair loss, despite some anecdotal reports of hair thinning. The discussion emphasizes that these reports are not supported by scientific evidence.
The user has mostly recovered hair density using finasteride, alternating oral and topical minoxidil, and occasional dermarolling, but the crown area is still struggling. Advice includes continuing treatment for up to 24 months and possibly consulting a doctor if issues persist.
The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
Creatine may affect hair loss by reducing PGE2 levels, which could influence hair growth. The discussion highlights the need for more research on this potential mechanism.
The conversation discusses Scube3, a seemingly new and obscure treatment for hair loss, with limited information available and a link to a patient intake form.
The user has been using a hair regrowth regimen for 9-10 months, including topical finasteride and minoxidil, various oils, and supplements like multivitamins and omega-3. They observed fine hairs returning and a change in scalp texture after adding cinnamon oil, questioning if this indicates positive hair regrowth.
A user with kidney disease and high blood pressure experienced hair thinning, especially around the vertex. They are currently using finasteride and oral minoxidil but are considering whether to resume blood pressure medication despite managing symptoms with diet and exercise.
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
Saw palmetto's fatty acids, particularly lauric and linoleic acids, inhibit enzymes linked to hair loss, while sterols like beta-sitosterol are less effective due to poor absorption. The conversation questions which specific compounds in saw palmetto contribute to its anti-androgenic effects.
The conversation discusses changes in scalp texture and appearance in areas of hair loss, with concerns about the suitability of these areas for hair transplants. Users mention issues like fibrosis, inflammation, and thinner skin, advising caution and consultation with clinics before proceeding with transplants.
A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.
Creatine may increase DHT levels, but its impact on hair loss is unclear and not well-studied. Many users report no significant hair loss while using creatine alongside finasteride, though some experience increased shedding.
The user experienced hair repigmentation and attributes improvements in hair and overall health to a carnivore diet, Boron, and Selenium supplementation. They stopped using finasteride after 20 years, noticed increased testosterone and libido, and observed hair regrowth with RU58841.
The conversation discusses concerns about Scube3's effectiveness and potential cancer link. It questions whether Scube3 can regrow hair and how well it works according to researchers.
The user shared progress photos of hair regrowth using copper peptides and NAD+ over five months. Another user commented on the lighting, and another praised the progress.
Cbum's hair transplant is criticized for looking unnatural and not blending well, with some suggesting better results were expected given his resources. Discussions also cover the effects of steroids and finasteride on hair loss and muscle growth.
Pyrilutamide's systemic degradation is unclear, unlike fluridil, which becomes inactive in the body. The discussion focuses on whether pyrilutamide shares this property.
Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.
A user lost 60% hair density in 4 months, started finasteride and microneedling, and has greasy, flaky, yellowish scalp. They are awaiting biopsy results, and another user suggested trying ketoconazole shampoo.
A healthy scalp barrier is crucial for hair growth, and ceramides may play a key role in maintaining it. The conversation suggests that focusing on scalp health, alongside treatments like Minoxidil, Finasteride, and RU58841, could improve hair follicle health.
User shares new hair growth stack including oral minox, daily rolling with minox application, niacin, and Dutasteride. Excited about progress and plans to update in two months.
Topical Calcipotriol (vitamin D derivative) may help with hair regrowth, especially for alopecia areata. The user wonders if adding classic vitamin D to lotions like Minoxidil could have a similar effect.
A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.